What is Enliven Therapeutics's G&A?

Enliven Therapeutics (ELVN) reported G&A of $7.14M in Q1 2026.

How has Enliven Therapeutics's G&A changed year-over-year?

Enliven Therapeutics's G&A increased by 5.0% year-over-year, from $6.8M to $7.14M.

What is the long-term trend for Enliven Therapeutics's G&A?

Over 4 years (2021 to 2025), Enliven Therapeutics's G&A has grown at a 27.0% compound annual growth rate (CAGR), from $13M to $33.8M.

Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.

Enliven Therapeutics ELVN G&A

G&A at other companies

Relay Therapeutics, Inc.RLAY

$11.03M-41.2%

Arcus BiosciencesRCUS

$29M+3.6%

Intellia TherapeuticsNTLA

$34.84M+20.1%

Nuvalent, Inc.NUVL

$35.8M+75.5%

Crinetics PharmaceuticalsCRNX

$50.83M+43.1%

Kymera TherapeuticsKYMR

$20.36M+25.1%

Other financials

Income statement

See full

Operating income-$27.8M+12.2%

Net income-$23.6M+17.2%

EPS (diluted)-$0.38+33.3%

Balance sheet

See full

Cash & equivalents$132.2M+30.0%

Total debt$302.0K-56.9%

Total equity$453.4M+57.3%

Total assets$464.9M+53.6%

Cash flow

See full

Operating cash flow-$19.3M+20.0%

CapEx--100%

Free cash flow-$19.3M+20.1%

Valuation

See full

Market cap$3.47B+143%

Enterprise value$3.34B+156%

Returns & leverage

See full

Return on equity-26.6%-3.5pp

Debt / equity0×0.0×

Current ratio40.3×+19.3×

Where this comes from

Reported directly by Enliven Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.

The official record: Enliven Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Enliven Therapeutics's g&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Enliven Therapeutics's G&A?: Enliven Therapeutics (ELVN) reported G&A of $7.14M in Q1 2026.
How has Enliven Therapeutics's G&A changed year-over-year?: Enliven Therapeutics's G&A increased by 5.0% year-over-year, from $6.8M to $7.14M.
What is the long-term trend for Enliven Therapeutics's G&A?: Over 4 years (2021 to 2025), Enliven Therapeutics's G&A has grown at a 27.0% compound annual growth rate (CAGR), from $13M to $33.8M.
What does G&A mean?: Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.